Australia's PBAC says Enbrel biosimilar can be substituted

Australia's Pharmaceutical Benefits Advisory Committee (PBAC) has given pharmacists the authority to substitute the biosimilar Brenzys etanercept for its reference product, autoimmune drug Enbrel etanercept.

Merck & Co. Inc. (NYSE:MRK) holds rights to Brenzys in Australia under a partnership with Samsung Bioepis, a JV between Biogen Inc. (NASDAQ:BIIB) and Samsung Group (Seoul, South Korea). Pfizer Inc. (NYSE:PFE) holds Enbrel's rights outside the U.S. and Canada under a deal with Amgen Inc. (NASDAQ:AMGN). ...